Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manyi Xu

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Journal of Cancer Research and Clinical Oncology|November 17, 2023
Efficacy of rechallenge immunotherapy after immune monotherapy resistance in patients with advanced non-small cell lung cancerManyi Xu, Yue Hao, Zheng Shi, et al.
Journal of Thoracic Disease|September 11, 2023
Efficacy and safety of immune checkpoint inhibitors in lung large-cell neuroendocrine carcinomaZheng Shi, Jingwen Wei, Manyi Xu, et al.
Journal of Thoracic Disease|May 17, 2023
Immune checkpoint inhibitors beyond first-line progression with prior immunotherapy in patients with advanced non-small cell lung cancerManyi Xu, Yue Hao, Xiaohong Zeng, et al.
Investigational New Drugs|October 30, 2023
Clinical characteristics and prognostic impact of immune checkpoint inhibitor-associated myocarditis in advanced non-small cell lung cancerLan Xu, Manyi Xu, Wei Sun, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 25, 2024
Pyrotinib as a salvage treatment for patients with HER-2 positive advanced lung adenocarcinoma after the progression of afatinib treatmentManyi Xu, Yanhua Wang, Keda Shao, et al.
Journal of Thoracic Disease|April 15, 2024
Clinical characteristics and prognostic implications of immune-related hepatitis in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: a retrospective studyManyi Xu, Lan Xu, Yue Hao, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 16, 2024
Comparison of the efficacy and safety of anlotinib monotherapy or anlotinib plus immune checkpoint inhibitor for advanced small cell lung cancer with brain metastasesManyi Xu, Keda Shao, Yanhua Wang, et al.
Journal of Thoracic Disease|June 18, 2025
Efficacy evaluation of tyrosine kinase inhibitors for advanced non-small cell lung cancer patients with leptomeningeal metastasisYanhua Wang, Yue Hao, Manyi Xu, et al.
European Journal of Medicinal Chemistry|May 4, 2019
Design, synthesis and antitumor evaluation of novel celastrol derivativesManyi Xu, Na Li, Zihao Zhao, et al.
Therapeutic Advances in Medical Oncology|May 13, 2024
Assessment of efficacy and safety of MET tyrosine kinase inhibitors in non-small-cell lung cancer patients with MET alterationsYanhua Wang, Manyi Xu, Ke Wang, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Journal of Cancer Research and Clinical Oncology|November 17, 2023
Efficacy of rechallenge immunotherapy after immune monotherapy resistance in patients with advanced non-small cell lung cancerManyi Xu, Yue Hao, Zheng Shi, et al.
Journal of Thoracic Disease|September 11, 2023
Efficacy and safety of immune checkpoint inhibitors in lung large-cell neuroendocrine carcinomaZheng Shi, Jingwen Wei, Manyi Xu, et al.
Journal of Thoracic Disease|May 17, 2023
Immune checkpoint inhibitors beyond first-line progression with prior immunotherapy in patients with advanced non-small cell lung cancerManyi Xu, Yue Hao, Xiaohong Zeng, et al.
Investigational New Drugs|October 30, 2023
Clinical characteristics and prognostic impact of immune checkpoint inhibitor-associated myocarditis in advanced non-small cell lung cancerLan Xu, Manyi Xu, Wei Sun, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 25, 2024
Pyrotinib as a salvage treatment for patients with HER-2 positive advanced lung adenocarcinoma after the progression of afatinib treatmentManyi Xu, Yanhua Wang, Keda Shao, et al.
Journal of Thoracic Disease|April 15, 2024
Clinical characteristics and prognostic implications of immune-related hepatitis in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: a retrospective studyManyi Xu, Lan Xu, Yue Hao, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 16, 2024
Comparison of the efficacy and safety of anlotinib monotherapy or anlotinib plus immune checkpoint inhibitor for advanced small cell lung cancer with brain metastasesManyi Xu, Keda Shao, Yanhua Wang, et al.
Journal of Thoracic Disease|June 18, 2025
Efficacy evaluation of tyrosine kinase inhibitors for advanced non-small cell lung cancer patients with leptomeningeal metastasisYanhua Wang, Yue Hao, Manyi Xu, et al.
European Journal of Medicinal Chemistry|May 4, 2019
Design, synthesis and antitumor evaluation of novel celastrol derivativesManyi Xu, Na Li, Zihao Zhao, et al.
Therapeutic Advances in Medical Oncology|May 13, 2024
Assessment of efficacy and safety of MET tyrosine kinase inhibitors in non-small-cell lung cancer patients with MET alterationsYanhua Wang, Manyi Xu, Ke Wang, et al.
Pageof 5